The University of Chicago Header Logo

Connection

Andrzej Jakubowiak to Treatment Outcome

Back to Details
This is a "connection" page, showing publications Andrzej Jakubowiak has written about Treatment Outcome.
Andrzej Jakubowiak
Connection Strength
1.130
Treatment Outcome
  1. Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024 05 29; 14(1):87.
    View in: PubMed
    Score: 0.097
  2. Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma. Oncologist. 2022 07 05; 27(7):e589-e596.
    View in: PubMed
    Score: 0.085
  3. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol. 2019 08; 186(4):549-560.
    View in: PubMed
    Score: 0.068
  4. Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States. Expert Rev Hematol. 2017 12; 10(12):1107-1119.
    View in: PubMed
    Score: 0.062
  5. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016 06 09; 127(23):2833-40.
    View in: PubMed
    Score: 0.055
  6. Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica. 2014 Sep; 99(9):e162-4.
    View in: PubMed
    Score: 0.049
  7. Introduction: recent advances in the understanding and management of multiple myeloma. Semin Oncol. 2013 Oct; 40(5):535-6.
    View in: PubMed
    Score: 0.046
  8. Evolving strategies in the initial treatment of multiple myeloma. Semin Oncol. 2013 Oct; 40(5):592-601.
    View in: PubMed
    Score: 0.046
  9. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia. 2013 Dec; 27(12):2351-6.
    View in: PubMed
    Score: 0.045
  10. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012 Aug 30; 120(9):1801-9.
    View in: PubMed
    Score: 0.042
  11. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. Br J Haematol. 2012 Aug; 158(4):472-80.
    View in: PubMed
    Score: 0.042
  12. Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial. Leuk Lymphoma. 2011 Jul; 52(7):1271-80.
    View in: PubMed
    Score: 0.039
  13. Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma. Clin Adv Hematol Oncol. 2011 Apr; 9(4):1-15.
    View in: PubMed
    Score: 0.039
  14. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023 02; 24(2):139-150.
    View in: PubMed
    Score: 0.022
  15. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022 01 27; 139(4):492-501.
    View in: PubMed
    Score: 0.021
  16. Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial. BMC Cancer. 2021 Jun 02; 21(1):659.
    View in: PubMed
    Score: 0.020
  17. Sex differences in outcomes in multiple myeloma. Br J Haematol. 2021 02; 192(3):e66-e69.
    View in: PubMed
    Score: 0.019
  18. Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis. Blood Cancer J. 2020 08 07; 10(8):80.
    View in: PubMed
    Score: 0.019
  19. Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies. Clin Lymphoma Myeloma Leuk. 2020 07; 20(7):480-489.
    View in: PubMed
    Score: 0.018
  20. Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. Adv Ther. 2020 04; 37(4):1464-1478.
    View in: PubMed
    Score: 0.018
  21. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020 01 11; 395(10218):132-141.
    View in: PubMed
    Score: 0.018
  22. A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia. Clin Cancer Res. 2019 08 15; 25(16):4907-4916.
    View in: PubMed
    Score: 0.017
  23. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2019 08 01; 134(5):421-431.
    View in: PubMed
    Score: 0.017
  24. Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. Blood Cancer J. 2019 01 04; 9(1):3.
    View in: PubMed
    Score: 0.017
  25. Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy. Pol Arch Intern Med. 2017 06 30; 127(6):392-400.
    View in: PubMed
    Score: 0.015
  26. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer J. 2017 04 21; 7(4):e554.
    View in: PubMed
    Score: 0.015
  27. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol. 2017 05; 177(3):404-413.
    View in: PubMed
    Score: 0.015
  28. Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy. Oncotarget. 2016 Aug 30; 7(35):56726-56736.
    View in: PubMed
    Score: 0.014
  29. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016 Apr 09; 387(10027):1551-1560.
    View in: PubMed
    Score: 0.014
  30. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015 Dec; 2(12):e516-27.
    View in: PubMed
    Score: 0.013
  31. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res. 2016 Jan 01; 22(1):34-43.
    View in: PubMed
    Score: 0.013
  32. Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. Leuk Lymphoma. 2015; 56(10):2959-61.
    View in: PubMed
    Score: 0.013
  33. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014 Aug 14; 124(7):1038-46.
    View in: PubMed
    Score: 0.012
  34. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014 Mar 06; 123(10):1461-9.
    View in: PubMed
    Score: 0.012
  35. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014 Mar 20; 123(12):1826-32.
    View in: PubMed
    Score: 0.012
  36. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012 Sep; 158(6):739-48.
    View in: PubMed
    Score: 0.011
  37. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012 Jun 14; 119(24):5661-70.
    View in: PubMed
    Score: 0.010
  38. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol. 2011 Jun; 86(6):484-7.
    View in: PubMed
    Score: 0.010
  39. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 05; 116(5):679-86.
    View in: PubMed
    Score: 0.009
  40. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol. 2008 Oct; 143(2):222-9.
    View in: PubMed
    Score: 0.008
  41. The research mission in myeloma. Leukemia. 2009 Feb; 23(2):422-3; author reply 423-4.
    View in: PubMed
    Score: 0.008
  42. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007 Nov 15; 110(10):3557-60.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.